Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms MERIT-2
- Sponsors Actelion Pharmaceuticals
- 29 Jan 2018 Planned End Date changed from 28 Sep 2018 to 22 Dec 2020.
- 29 Jan 2018 Planned primary completion date changed from 28 Sep 2018 to 22 Dec 2020.
- 21 Jun 2017 Planned End Date changed from 1 Jun 2018 to 28 Sep 2018.